List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4086972/publications.pdf Version: 2024-02-01



ΔΛΙΙΙ **Ο Τ**ΛΙ

#	Article	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.7	6,781
2	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2010, 69, 1580-1588.	0.9	2,994
3	Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8284-8289.	7.1	742
4	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2012, 71, 638-641.	0.9	354
5	The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis and Rheumatism, 2000, 43, 2619-2633.	6.7	353
6	Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis and Rheumatism, 1998, 41, 1481-1488.	6.7	275
7	Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis and Rheumatism, 2000, 43, 593.	6.7	263
8	Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis and Rheumatism, 2002, 46, 2034-2038.	6.7	262
9	Inhibitor of nuclear factor ?B kinase ? is a key regulator of synovial inflammation. Arthritis and Rheumatism, 2001, 44, 1897-1907.	6.7	236
10	Therapeutic options for targeting inflammatory osteoarthritis pain. Nature Reviews Rheumatology, 2019, 15, 355-363.	8.0	227
11	Reduction of synovial inflammation after anti-cd4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis and Rheumatism, 1995, 38, 1457-1465.	6.7	185
12	Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology, 2017, 13, 463-475.	8.0	175
13	Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Annals of the Rheumatic Diseases, 2019, 78, 179-185.	0.9	163
14	Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis and Rheumatism, 2000, 43, 1820-1830.	6.7	161
15	Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Annals of the Rheumatic Diseases, 2013, 72, 329-336.	0.9	158
16	Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Ameliorates Disease in Rat Collagen-Induced Arthritis. PLoS ONE, 2014, 9, e104530.	2.5	157
17	Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1654-1658.	0.9	150
18	The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Annals of the Rheumatic Diseases, 2016, 75, 422-429.	0.9	134

#	Article	IF	CITATIONS
19	MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase lb/lla randomised, double-blind, placebo-controlled, dose-escalation trial. Annals of the Rheumatic Diseases, 2015, 74, 1058-1064.	0.9	133
20	MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 499-505.	0.9	130
21	Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis and Rheumatism, 1999, 42, 650-658.	6.7	125
22	Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Annals of the Rheumatic Diseases, 2017, 76, 277-285.	0.9	118
23	Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis and Rheumatism, 2008, 58, 1582-1589.	6.7	114
24	Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. , 1998, 186, 75-81.		107
25	Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: Findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis and Rheumatism, 2000, 43, 1488-1495.	6.7	106
26	Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Annals of the Rheumatic Diseases, 2011, 70, 423-427.	0.9	101
27	Detection of bacterial DNA in serial synovial samples obtained during antibiotic treatment from patients with septic arthritis. Arthritis and Rheumatism, 1999, 42, 2198-2203.	6.7	87
28	Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 75.	3.5	85
29	The effects of interferon-Î ² treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2000, 43, 270.	6.7	84
30	Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines. Arthritis and Rheumatism, 2000, 43, 2160-2168.	6.7	79
31	Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. European Journal of Drug Metabolism and Pharmacokinetics, 2006, 31, 109-116.	1.6	77
32	Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Annals of the Rheumatic Diseases, 2013, 72, 337-344.	0.9	74
33	DNA Methylome Signature in Synoviocytes From Patients With Early Rheumatoid Arthritis Compared to Synoviocytes From Patients With Longstanding Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 1978-1980.	5.6	74
34	Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program. PLoS ONE, 2014, 9, e87379.	2.5	71
35	Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression. Annals of the Rheumatic Diseases, 2016, 75, 430-438.	0.9	68
36	Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. Rheumatology, 2016, 55, 607-614.	1.9	65

#	Article	IF	CITATIONS
37	Brief Report: Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the Atâ€Risk and Earliest Phases of Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 70-76.	5.6	57
38	Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1924-1930.	0.9	50
39	MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Annals of the Rheumatic Diseases, 2016, 75, 170-177.	0.9	48
40	Poor Expression of T Cell-Derived Cytokines and Activation and Proliferation Markers in Early Rheumatoid Synovial Tissue. Clinical Immunology and Immunopathology, 1998, 88, 84-90.	2.0	47
41	JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1763-1771.	0.9	46
42	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Seminars in Arthritis and Rheumatism, 2019, 48, 967-975.	3.4	46
43	Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool. Annals of the Rheumatic Diseases, 2012, 71, 1911-1912.	0.9	45
44	Tie2 Signaling Cooperates with TNF to Promote the Pro-Inflammatory Activation of Human Macrophages Independently of Macrophage Functional Phenotype. PLoS ONE, 2014, 9, e82088.	2.5	44
45	Stromal cell markers are differentially expressed in the synovial tissue of patients with early arthritis. PLoS ONE, 2017, 12, e0182751.	2.5	43
46	ls treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the Rheumatic Diseases, 2020, 79, 453-459.	0.9	43
47	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics Journal, 2018, 18, 528-538.	2.0	42
48	Detection ofBorrelia burgdorferi sensu stricto by reverse line blot in the joints of Dutch patients with Lyme arthritis. Arthritis and Rheumatism, 1999, 42, 1473-1480.	6.7	35
49	Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Annals of the Rheumatic Diseases, 2015, 74, 1603-1611.	0.9	35
50	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. PLoS ONE, 2014, 9, e87645.	2.5	34
51	Tertiary Lymphoid Structures in Rheumatoid Arthritis. American Journal of Pathology, 2015, 185, 1935-1943.	3.8	34
52	Synovial IL-21/TNF-producing CD4+ T cells induce joint destruction in rheumatoid arthritis by inducing matrix metalloproteinase production by fibroblast-like synoviocytes. Journal of Leukocyte Biology, 2017, 101, 775-783.	3.3	33
53	Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the atâ€risk phase of autoantibody positive rheumatoid arthritis. European Journal of Immunology, 2016, 46, 2812-2821.	2.9	31
54	Somatic Variation of T-Cell Receptor Genes Strongly Associate with HLA Class Restriction. PLoS ONE, 2015, 10, e0140815.	2.5	30

#	Article	IF	CITATIONS
55	Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 35.	3.5	29
56	14-3-3ĥ Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 1587-1594.	2.0	28
57	Smelling the Diagnosis: The Electronic Nose as Diagnostic Tool in Inflammatory Arthritis. A Case-Reference Study. PLoS ONE, 2016, 11, e0151715.	2.5	27
58	Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire. Annals of the Rheumatic Diseases, 2019, 78, 1339-1345.	0.9	26
59	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	0.9	25
60	Human lymph-node CD8+ T cells display an altered phenotype during systemic autoimmunity. Clinical and Translational Immunology, 2016, 5, e67.	3.8	23
61	Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology, 2018, 57, 909-920.	1.9	21
62	Local Synovial Engagement of Angiogenic TIEâ€2 Is Associated With the Development of Persistent Erosive Rheumatoid Arthritis in Patients With Early Arthritis. Arthritis and Rheumatism, 2013, 65, 3073-3083.	6.7	20
63	Nuclear Factor-l̂®â€"inducing Kinase Is Expressed in Synovial Endothelial Cells in Patients with Early Arthritis and Correlates with Markers of Inflammation: A Prospective Cohort Study. Journal of Rheumatology, 2015, 42, 1573-1581.	2.0	20
64	Distinctive expression of T cell guiding molecules in human autoimmune lymph node stromal cells upon TLR3 triggering. Scientific Reports, 2018, 8, 1736.	3.3	20
65	CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis. Arthritis Research and Therapy, 2015, 17, 6.	3.5	19
66	Dynamic Contrastâ€Enhanced Magnetic Resonance Imaging Using Pharmacokinetic Modeling: Initial Experience in Patients With Early Arthritis. Arthritis and Rheumatology, 2016, 68, 587-596.	5.6	19
67	Promotion of macrophage activation by Tie2 in the context of the inflamed synovia of rheumatoid arthritis and psoriatic arthritis patients. Rheumatology, 2020, 59, 426-438.	1.9	19
68	Molecular Characterization of Human Lymph Node Stromal Cells During the Earliest Phases of Rheumatoid Arthritis. Frontiers in Immunology, 2019, 10, 1863.	4.8	17
69	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. Journal of Rheumatology, 2020, 47, 809-819.	2.0	16
70	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <scp>Pharmacogenomicsâ€Driven</scp> Machine Learning Approach. Arthritis Care and Research, 2022, 74, 879-888.	3.4	15
71	A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin. Dermatology, 2012, 225, 298-303.	2.1	13
72	Increased Frequency of CD4+ Follicular Helper T and CD8+ Follicular T Cells in Human Lymph Node Biopsies during the Earliest Stages of Rheumatoid Arthritis. Cells, 2022, 11, 1104.	4.1	13

#	Article	IF	CITATIONS
73	Histological characteristics of ligament healing after bio-enhanced repair of the transected goat ACL. Journal of Experimental Orthopaedics, 2015, 2, 4.	1.8	12
74	Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2443-2450.	2.4	12
75	Analyzing synovial tissue samples. What can we learn about early rheumatoid arthritis, the heterogeneity of the disease, and the effects of treatment?. Journal of rheumatology Supplement, The, 2005, 72, 25-6.	2.2	12
76	Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's Disease. Frontiers in Immunology, 2015, 6, 625.	4.8	11
77	FHL2 regulates the resolution of tissue damage in chronic inflammatory arthritis. Annals of the Rheumatic Diseases, 2015, 74, 2216-2223.	0.9	9
78	Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon-Injury Model. PLoS ONE, 2015, 10, e0122836.	2.5	6
79	A2.15â€Relative Overexpression of Transmembrane Versus Soluble TNF in Human and Experimental Spondyloarthritis. Annals of the Rheumatic Diseases, 2013, 72, A9.3-A10.	0.9	5
80	Human Lymph Node Stromal Cells Have the Machinery to Regulate Peripheral Tolerance during Health and Rheumatoid Arthritis. International Journal of Molecular Sciences, 2020, 21, 5713.	4.1	5
81	Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis. Biomedicines, 2022, 10, 324.	3.2	4
82	Prevalence of Anti–Citrullinated Protein Antibodies and IgM Rheumatoid Factor in Firstâ€Degree Relatives of Dutch Rheumatoid Arthritis Patients. Arthritis and Rheumatology, 2015, 67, 3324-3326.	5.6	3
83	Summary of Sensitivity and Specificity for Psoriatic Arthritis in a South African Cohort according to Classification Criteria. Journal of Rheumatology, 2015, 42, 960-962.	2.0	3
84	Does the multi-biomarker disease activity score have diagnostic value in early rheumatoid arthritis and unclassified arthritis?. Annals of the Rheumatic Diseases, 2015, 74, 2097-2099.	0.9	3
85	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. Journal of Rheumatology, 2020, 47, 796-808.	2.0	3
86	Intracellular delivery of poly(I:C) induces apoptosis of fibroblast-like synoviocytes via an unknown dsRNA sensor. Biochemical and Biophysical Research Communications, 2016, 477, 343-349.	2.1	2
87	Rheumatoid Arthritis and Other Inflammatory Articular Diseases. , 2017, , 1105-1140.		1
88	Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. , 0, .		1
89	B cell receptor repertoire analysis in clinically involved and uninvolved skin of systemic sclerosis patients treated with CD20 depletion therapy: baseline and follow-up. Annals of the Rheumatic Diseases, 2011, 70, A62-A63.	0.9	0
90	Local downregulation of pre-B cell colony-enhancing factor/visfatin using an adeno-associated virus type 5 vector encoding a specific small hairpin RNA for PBEF results in amelioration of arthritis. Annals of the Rheumatic Diseases, 2011, 70, A77-A77.	0.9	0

#	Article	IF	CITATIONS
91	Stimulation of the cytosolic dsRNA sensor MDA-5 induces cell death in fibroblast-like synoviocytes. Annals of the Rheumatic Diseases, 2012, 71, A77.3-A78.	0.9	Ο
92	A5.31â€The Role of BOB1 in Rheumnatoid Arthritis: Potential Implications for Autoimmunity. Annals of the Rheumatic Diseases, 2013, 72, A41.3-A42.	0.9	0
93	Editorial - Lessons Learned from Synovial Tissue Analysis. Open Rheumatology Journal, 2011, 5, 98-99.	0.2	Ο